Bristol-Myers’ Opdivo ushers in a new era as the first I-O therapy approved in China
admin 15th June 2018 Uncategorised 0In a historic moment for China’s medical world, China’s Drug Administration on Friday approved Opdivo, the country’s first immuno-oncology therapy. For Bristol-Myers Squibb, though, the time for celebration won’t last long, as there’re many more to come, including its archnemesis Keytruda.
More: Bristol-Myers’ Opdivo ushers in a new era as the first I-O therapy approved in China
Source: fierce